Andrew Bellinger - 20 Jul 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
CSO & CMO
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Andrew Bellinger
Issuer symbol
VERV
Transactions as of
20 Jul 2022
Net transactions value
-$670,200
Form type
4
Filing time
22 Jul 2022, 17:00:35 UTC
Previous filing
15 Jul 2022
Next filing
27 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Options Exercise $27,800 +20,000 +302% $1.39* 26,629 20 Jul 2022 Direct
transaction VERV Common Stock Sale $698,000 -20,000 -75% $34.90 6,629 20 Jul 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Options Exercise $0 -20,000 -93% $0.000000 1,599 20 Jul 2022 Common Stock 20,000 $1.39 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2022.
F2 The option was granted on June 25, 2019 for 21,599 shares. The shares underlying the option vested on May 1, 2020.